TransMedics (TMDX) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Wed, May 6, 2026 astatine 9:41 AM CDT 42 min read

Image source: The Motley Fool.

Date

Tuesday, May 5, 2026, 4:30 p.m. ET

Call participants

• President and Chief Executive Officer — Waleed Hassanein

• Chief Financial Officer — Gerardo Hernandez

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

Waleed Hassanein: Thank you truthful much, Hannah. Good afternoon, everyone, and invited to TransMedics First Quarter 2026 Earnings Call. As always, joining maine contiguous is Gerardo Hernandez, our Chief Financial Officer. Our imaginativeness has been bold -- our imaginativeness has ever been bold and growth-oriented. Since inception, TransMedics has been relentless successful our pursuit to alteration organ transplant therapy by expanding utilization of donor organs and improving the objective outcomes of transplant patients passim -- done exertion and work innovation and by disrupting the presumption quo. To execute this, we've been deliberate yet assertive successful our strategical concern successful maturation initiatives.

We judge that 2026 is simply a captious and transformational twelvemonth that stands to cement TransMedics' near, mid- and semipermanent maturation trajectories and planetary marketplace position. In the U.S., we're actively engaged successful increasing our bosom and lung franchises by advancing our enhanced bosom and DENOVO lung programs to grow our objective grounds to enactment broader adoption. In parallel, we are besides completing the improvement of the OCS Kidney level utilizing our Gen 3.0 platform. Our OCS Kidney level volition alteration america to entree the largest conception of the planetary transplant market, which is kidney transplantation. This volition hap for the archetypal clip successful the past of TransMedics.

We powerfully judge that erstwhile regulatory approvals are successful hand, OCS Kidney volition thrust important maturation for our abdominal franchise. And we're not stopping here. We're besides actively engaged successful upgrading our heart, lung and liver devices to Gen 3.0 platform, which volition alteration america to summation important aboriginal operating leverage and summation objective adoption of the OCS level successful these captious organ transplant segments. Our maturation initiatives besides present spell beyond lukewarm perfusion. We precocious unveiled the TransMedics Controlled Hypothermic Organ Preservation System, oregon CHOPS. CHOPS is designed to grow our merchandise offering to screen caller segments of the transplant marketplace champion served with acold static storage.

And finally, our maturation initiatives present widen beyond the U.S. to important planetary markets. In Europe, we are undertaking a bold inaugural to replicate the NOP objective work and transplant logistics exemplary to catalyze European OCS adoption and perchance grow our full addressable market. I volition supply details connected each of these breathtaking initiatives connected today's call. As you tin spot from our ongoing maturation initiatives, our absorption remains connected semipermanent worth instauration with continued concern crossed each pillar of our maturation strategy.